Clarence Kvart
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Clarence Kvart has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Anders Eriksson
Minerva Foundation Institute for Medical Research, Helsinki, Finland
3 shared publicationsAnna-Kaisa Järvinen
Department of Clinical Veterinary Sciences, Faculty of Veterinary Medicine, Helsinki University, Finland
3 shared publicationsAnna Tidholm
Albano (Tidholm) Animal Hospitals, Stockholm, Sweden
2 shared publicationsBjörn Åblad
Blå Stjärnan Animal Hospital, Gothenburg, Sweden (Åblad)
2 shared publicationsEllen Bjerkås
Norwegian School of Veterinary Science Department of Clinical Studies (Bjerkås) Oslo
2 shared publicationsErik Ahlgren
Sandvi-ken Animal Hospital, Sandviken (Bsenko, Ahlgren)
2 shared publications
Latest Publications
- 1 March 2005
- Published by Georg Thieme Verlag KG in veterinär spiegel
- Vol. 15 (03) , 9-12
Mitralklappenerkrankung beim Hund – neue Erkenntnisse
- 1 March 2005
- Published by Georg Thieme Verlag KG in veterinär spiegel
- Vol. 15 (03) , 9-12
Mitralklappenerkrankung beim Hund – neue Erkenntnisse
- 1 January 2003
- Published by Wiley in Journal of Veterinary Internal Medicine
- Vol. 17 (6) , 824-829
Increased Pulmonary Transit Times in Asymptomatic Dogs with Mitral Regurgitation
- 1 January 2003
- Published by Wiley in Journal of Veterinary Internal Medicine
- Vol. 17 (6) , 824-829
Increased Pulmonary Transit Times in Asymptomatic Dogs with Mitral Regurgitation
- 1 January 2002
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 16 (1) , 80-88
Efficacy of Enalapril for Prevention of Congestive Heart Failure in Dogs with Myxomatous Valve Disease and Asymptomatic Mitral Regurgitation
We evaluated the long-term effect of early angiotensin-converting enzyme (ACE) inhibition (enalapril maleate) as monotherapy to postpone or prevent congestive heart failure (CHF) in asymptomatic dogs with mitral regurgitation (MR) attributable to myxomatous valvular disease (MVD) in a prospective, randomized, double-blinded, placebo-controlled multicenter trial involving 14 centers in Scandinavia. Two hundred twenty-nine Cavalier King Charles (CKC) Spaniels with MR attributable to MVD but no signs of CHF were randomly allocated to treatment with enalapril 0.25–0.5 mg daily (n = 116) or to placebo groups (n = 113). Each dog was evaluated by physical examination, electrocardiography, and thoracic radiography at entry and every 12 months (±30 days). The number of dogs developing heart failure was similar in the treatment and placebo groups (n = 50 [43%] and n = 48 [42%], respectively; P= .99). The estimated means, adjusted for censored observations, for the period from initiation of therapy to heart failure were 1,150 ± 50 days for dogs in the treatment group and 1,130 ± 50 days for dogs in the placebo group (P= .85). When absence or presence of cardiomegaly at the entrance of the trial was considered, there were still no differences between the treatment and placebo groups (P= .98 and .51, respectively). Multivariate analysis showed that enalapril had no significant effect on the time from initiation of therapy to heart failure (P= .86). Long-term treatment with enalapril in asymptomatic dogs with MVD and MR did not delay the onset of heart failure regardless of whether or not cardiomegaly was present at initiation of the study.
- 1 January 2002
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 16 (1) , 80-88
Efficacy of Enalapril for Prevention of Congestive Heart Failure in Dogs with Myxomatous Valve Disease and Asymptomatic Mitral Regurgitation
We evaluated the long-term effect of early angiotensin-converting enzyme (ACE) inhibition (enalapril maleate) as monotherapy to postpone or prevent congestive heart failure (CHF) in asymptomatic dogs with mitral regurgitation (MR) attributable to myxomatous valvular disease (MVD) in a prospective, randomized, double-blinded, placebo-controlled multicenter trial involving 14 centers in Scandinavia. Two hundred twenty-nine Cavalier King Charles (CKC) Spaniels with MR attributable to MVD but no signs of CHF were randomly allocated to treatment with enalapril 0.25–0.5 mg daily (n = 116) or to placebo groups (n = 113). Each dog was evaluated by physical examination, electrocardiography, and thoracic radiography at entry and every 12 months (±30 days). The number of dogs developing heart failure was similar in the treatment and placebo groups (n = 50 [43%] and n = 48 [42%], respectively; P= .99). The estimated means, adjusted for censored observations, for the period from initiation of therapy to heart failure were 1,150 ± 50 days for dogs in the treatment group and 1,130 ± 50 days for dogs in the placebo group (P= .85). When absence or presence of cardiomegaly at the entrance of the trial was considered, there were still no differences between the treatment and placebo groups (P= .98 and .51, respectively). Multivariate analysis showed that enalapril had no significant effect on the time from initiation of therapy to heart failure (P= .86). Long-term treatment with enalapril in asymptomatic dogs with MVD and MR did not delay the onset of heart failure regardless of whether or not cardiomegaly was present at initiation of the study.
- Open Access
- 1 January 2002
- Published by Wiley in Journal of Veterinary Internal Medicine
- Vol. 16 (1) , 80-88
Efficacy of Enalapril for Prevention of Congestive Heart Failure in Dogs with Myxomatous Valve Disease and Asymptomatic Mitral Regurgitation
- 1 January 2002
- Published by Wiley in Journal of Veterinary Internal Medicine
- Vol. 16 (1) , 80-88
Open AccessEfficacy of Enalapril for Prevention of Congestive Heart Failure in Dogs with Myxomatous Valve Disease and Asymptomatic Mitral Regurgitation